Cognitive Behavior Therapy for People with Schizophrenia

For decades, psychologists have devised many treatment regimes for schizophrenia patients, with varying degrees of success and effectiveness. There have been great obstacles in their efforts, mainly due to the fact that patients of schizophrenia lack insight into their impaired conditions. Often patients refuse treatment of any kind because they do not perceive any mental illness associated with their behaviour. In particular, individuals suffering from paranoid schizophrenia regard therapy as intrusions from hostile outside forces, which reduces compliance on the part of the patient (Davison & Neale,1998). Other problems with treatment programs for schizophrenic’s is that they suffer from both positive and negative symptoms, each requiring different type of treatments. In order to combat the difficulty of treating schizophrenia, several techniques have been devised; psychoanalytic therapy, behavioural therapy, family therapy and most predominantly, drug therapies. Drug therapy is the primary form of treatment implemented at the onset of schizophrenia. The drug clozapine is very effective for many patients who do not respond to initial drug treatment programs and treats both the positive and negative symptoms of schizophrenia (Advokat et al., 1999; Robinson et al., 1999). Moreover, a reduction in negative symptoms has also been noted to occur as individuals are treated with amisulpride and (Danion et al., 1999). The use of newer drugs to treat schizophrenia has produced fewer side effects in most patients. However, it has been found that although the use of risperidone to treat patients is very effective in treating the symptoms, there may be negative side effects for women using the drugs (Caracci,1999). As well, haloperidol has been one of the most widely used drugs for treating schizophrenia and is very effective, but if it is over-prescribed it could result in severe side effects for the patient (Yasui et al., 1999). Despite the possible

References: Advokat, C.D., L.J. Bertman, and J.E Comaty Jr. 1999. Clinical outcome to clozapine treatment in chronic psychiatric inpatients. Prog. Neuro-Psychopharmacol. & Biol. Psychiat, 23:1-14. Caracci, G. 1999. Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics. J. Clin. Psychopharmacol, 2:194-196. Danion, J.M, W. Rein, O. Fleurot and Amisulpride Study Group. 1999. Improvement of schizophrenia patients with primary negative sympotms treated with amisulpride. Am J. Psychiatry, 156:610-616. Davison G.C. and J.M. Neale. 1999. Abnormal Psychology. USA: John Wiley & Sons, Inc. Robinson, D. G., M.G. Woerner, J.M. Alvir, S. Geisler, A. Koreen, B. Sheitman, M. Chakos, D. Mayerhoff, R. Bilder, R. Goldman, and J.A. Lieberman. 1999. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry, 156:544-549. Yasui, N., T. Kondo, K. Otani, H. Furukori, K. Mihara, A. Suzuki, S. Kaneko and Y. Inoue. 1999. Effects of itraconazole on the steady state plasma concentrations of haloperidole and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. Journal of Clinical Psychopharmacology, 19:149-154.